Related Experiment Videos
Strategies for the management of diabetic dyslipidaemia
1Department of Medicine, University of Helsinki, Finland. Maaria.Puupponen@huch.fi
Insights
Type 2 diabetes significantly increases cardiovascular disease risk beyond traditional factors. Managing hyperglycemia, dyslipidemia, and lowering LDL cholesterol are crucial for patients with type 2 diabetes.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Syndrome
Background:
- Atherosclerosis is a major complication of type 2 diabetes, contributing to a 3-fold higher cardiovascular disease mortality rate.
- Traditional cardiovascular risk factors do not fully explain the elevated risk in type 2 diabetes patients.
- Hyperglycemia and dyslipidemia are increasingly recognized as key contributors to excess cardiovascular risk in this population.
Purpose of the Study:
- To investigate the link between hyperglycemia, dyslipidemia, and increased cardiovascular risk in type 2 diabetes.
- To explore the atherogenic properties of low-density lipoprotein (LDL) cholesterol in type 2 diabetes patients.
- To recommend strategies for mitigating cardiovascular risk in individuals with type 2 diabetes.
Main Methods:
- Review of prospective clinical studies implicating hypertriglyceridemia.
- Analysis of data on LDL-cholesterol atherogenicity in type 2 diabetes.
- Examination of the role of small, dense LDL particles in endothelial dysfunction.
Main Results:
- Hypertriglyceridemia is implicated in cardiovascular risk in type 2 diabetes.
- LDL-cholesterol appears more atherogenic in type 2 diabetes patients.
- Small, dense LDL particles may contribute to endothelial dysfunction and increased atherogenicity.
Conclusions:
- Aggressive management of hyperglycemia and dyslipidemia is essential for type 2 diabetes patients.
- Lowering LDL cholesterol and triglyceride levels is recommended.
- Mandatory global risk assessment should accompany treatment strategies.
Abstract:
Atherosclerosis, the complication most prominently associated with type 2 diabetes and cardiovascular disease, represents a major burden for both individuals and society. Mortality rates associated with cardiovascular disease among patients with type 2 diabetes are at least 3 times those in the general population, and although 'traditional' cardiovascular risk factors affect patients with this disorder as they do other individuals, they do not account for the excess risk attached to type 2 diabetes. There is a growing body of evidence to show that hyperglycaemia and dyslipidaemia are connected with this excess cardiovascular risk: hypertriglyceridaemia has been implicated in several prospective clinical studies, and available data suggest that low density lipoprotein (LDL)-cholesterol is more atherogenic in patients with type 2 diabetes than in other individuals. It is possible that this increased atherogenicity is associated with a preponderance of small, dense LDL particles that are more prone to oxidation and glycation than larger fractions and that may be involved in endothelial dysfunction. These findings lead to the recommendation of mandatory global risk assessment, accompanied by good glycaemic control, aggressive lowering of serum levels of LDL-cholesterol and maintenance of serum levels of triglyceride at the lowest possible level in patients with type 2 diabetes.